783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707 | Haematologica
Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R
Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R
783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ
COMPARISON OF IMMUNOCHEMOTHERAPY WITH RITUXIMAB-DOSE-ADJUSTED EPOCH.... EHA Library. Vassilakopoulos T. Jun 9 2021; 325311
PDF) Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma | NEJM
Table 2 from Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. | Semantic Scholar
Low-Intensity Therapy in Adults with Burkitt's Lymphoma | NEJM
Dosing schedule of R-EPOCH regimen | Download Scientific Diagram
Treatment-related adverse reaction between R-CHOP and DA-EPOCH-R regimen | Download Scientific Diagram
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell. - ppt download
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study - The Lancet Haematology
Dosing schedule of EPOCH regimen | Download Scientific Diagram
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study | Haematologica
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. - Abstract ...
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma | NEJM
CONSORT diagram. ANC, absolute neutrophil count; CALGB, Cancer and... | Download Scientific Diagram
Chemotherapy and Rituximab for NHL: Results from the Dose-Adjusted EPOCH Study | Research To Practice
Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital | JCO Oncology Practice
Evaluating the incidence of chemotherapy-induced nausea and vomiting in patients with B-cell lymphoma receiving dose-adjusted EPOCH and rituximab - Emma Uchida, Matthew M Lei, Eric Roeland, Uvette Lou, 2022
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma | NEJM
